ABSINasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Absci Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$8.54+0.29 (+3.52%)

Close on Oct 19, 2026

Market cap: $1.34B
P/E (TTM): –
Dividend yield: –

Absci Corp income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	2.80	4.53	5.72	5.75	4.78	4.78
Research & Development	81	64	48	59	45	11
Selling, General & Admin	35	36	38	41	29	5.50
Operating Expenses	123	113	121	112	80	18
Operating Income	-120	-109	-116	-107	-75	-13
Interest Expense	0.21	0.57	1.01	0.97	3.43	0.63
Other Non-Operating Income	5.20	5.85	5.05	1.39	-35	-1.05
Asset Impairment Charges	–	0	21	0	–	0
Pretax Income	-115	-103	-110	-105	-110	-14
Income Tax Expense	0.07	0.07	0.10	-0.46	-8.90	0
Net Income	-115	-103	-111	-105	-101	-14
Net Income to Common	–	–	-111	-105	-103	-49
EPS (Basic)(per share)	-0.84	-0.94	-1.20	-1.15	-2.08	-3.19
EPS (Diluted)(per share)	-0.84	-0.94	-1.20	-1.15	-2.08	-3.19
Shares Outstanding (Basic, Weighted)(shares)	137	110	92	91	50	15
Shares Outstanding (Diluted, Weighted)(shares)	137	110	92	91	50	15
EBITDA	-109	-95	-102	-94	-69	-12

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -8084.5%
Net margin: -7756.4%
Return on equity, FY2025: -62.5%

Financial strength

Current ratio: 10.63
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 550.4%

Valuation

P/E ratio: –
Price to sales: 861.50
Price to book: 5.46
Dividend yield: –